January 2018- Volume 14, Issue 1

In this Issue

Diagnostics

A companion diagnostic with greater breadth

A companion diagnostic with greater breadth

FDA approves FoundationOne CDx companion diagnostic test for multiple solid tumors

Predicting lupus flares?

Predicting lupus flares?

Progentec completes first round of financing for $1.25 million

Extending the team-up against AD

Extending the team-up against AD

Continuation of Probiodrug and Crossbeta partnership to identify Alzheimer’s biomarkers

Research & Development

MicroRNAs and cancer

MicroRNAs and cancer

Salk Institute research illustrates how tumors outsmart immune response

Proud partnership

Proud partnership

Collaboration between Shire and Rani will evaluate approach to oral delivery of factor therapy for patients with hemophilia

Oxford Genetics and MeiraGTx tackle AAVs

Oxford Genetics and MeiraGTx tackle AAVs

The partners hope to develop a new production system that offers better yields and robustness

Culturing the unculturable

Culturing the unculturable

Biomillenia leverages QIAGEN bioinformatics in microbiome-on-a-chip discovery of unculturable microbes

A GalXC far, far away

A GalXC far, far away

Collaboration to explore RNA interference therapeutics for liver disease

Preclinical

Dialing in on a new DMD target

Dialing in on a new DMD target

Summit shares preclinical data supporting utrophin as a target for slowing muscular dystrophy progression

More answers on mavacamten

More answers on mavacamten

New research on drug elucidates successful HCM treatment mechanism

Hope for rare eye disease patients

Hope for rare eye disease patients

NanoViricides presents ‘highly effective’ treatment for acute retinal necrosis

Telemetry device advances metabolic disease research

Telemetry device advances metabolic disease research

Crown Bioscience and Data Sciences International partner to use device for long-term blood glucose monitoring

Business & Government Policy

A ‘softer’ Brexit?

A ‘softer’ Brexit?

U.K. government’s narrow defeat on amendment in withdrawal bill could have wide impact

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Mallinckrodt to acquire Sucampo for $1.2 billion

Mallinckrodt to acquire Sucampo for $1.2 billion

Transaction expected to be immediately accretive thanks to Amitiza and other Sucampo assets

Contract Services

A busy end to 2017

A busy end to 2017

PPD’s Q4 includes awards, a new NIH contract and expanded service offerings

A fivefold increase in sales

A fivefold increase in sales

ApconiX benefits from boost via pharma sector demand for drug safety expertise

Quotient Sciences acquires Pharmaterials

Quotient Sciences acquires Pharmaterials

Move strengthens and expands formulation and manufacturing services footprint in the U.K.

Clinical Trials

Cell replacement therapy

Cell replacement therapy

Companies collaborate in clinical trials of ex-vivo expanded cord blood stem cells

Clinical support for pGlu-Abeta targeting

Clinical support for pGlu-Abeta targeting

Probiodrug to start Phase 2b clinical trial of PQ912 in Alzheimer’s

New angle on immunotherapy

New angle on immunotherapy

Salk researchers get $2.5 million for pancreatic cancer trial involving vitamin D and Keytruda

More trials, more data sources, more problems

More trials, more data sources, more problems

Tufts survey reveals that plans to use greater range of patient data in clinical trials also means a need to prepare for management challenges

Novartis eyes nAMD

Novartis eyes nAMD

Results from Phase 3 studies support brolucizumab’s less-frequent dosing schedule

Discovery

Substance solubility

Substance solubility

SPA could expedite drug development

Compugen and JHU chart a new course

Compugen and JHU chart a new course

Collaboration researches first-in-class cancer therapy

A new friend in AMIGO2?

A new friend in AMIGO2?

Mount Sinai details the potential of transmembrane gene for halting melanoma growth

AI aids efforts in ALS

AI aids efforts in ALS

IBM’s Watson validates discovery of five new genes linked to the neurodegenerative disease

Feature

SLAS2018 Show Preview: Where the life sciences community converges

SLAS2018 Show Preview: Where the life sciences community converges

San Diego plays host to this year’s International Conference and Exhibition of the Society for Laboratory Automation and Screening. Read more to find out what's happening so you know what to expect when you're there, or why you should consider attending this or future SLAS conferences.

Editor's Focus

Editor’s focus: What looks like outrage might be necessity

Editor’s focus: What looks like outrage might be necessity

Companies, including pharmas and biotechs, do engage in greedy decisions at times, but does the high cost presented for a new gene therapy represent avarice or a need to recoup losses for bringing to market a powerful but still very new approach?

Commentary

Out of order: We are our stories

Out of order: We are our stories

A Hollywood screenwriter, a marine biologist and a science journalist walk into a lecture hall...and suggest you should tell more stories
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN June 2022 magazine issue front cover

Latest Issue  

• Volume 18 • Issue 6 • June 2022

June 2022

June 2022 Issue